The CSL blood products skills base is right up there at the cutting edge with all the right logistics to satisfy an enormous demand, but they are not a monopoly. I see MSB potentially the same - not only at the cutting edge but first mover advantage as well. Similarly they will never have a monopoly on stem science but who cares? I'll bet CSL would love to have the massive depth of untapped potential work targets that the Blaster has to come!!!
That's the big difference
Reminder, page-32
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |